1950
 
 - The Company was incorporated as a private limited company under
 the
 name of Dumex Ltd., on 21st November.  The Company manufacture and
 distribute sale and export of pharmaceuticals, agricultural and
 animal
 health products, pharmaceutical chemicals, nutritional products and
 items for personal, household and industrial use.
 
 - At its Mumbai plants, the Company manufactures pharmaceuticals and
 veterinary products and produces isonicotinic acid, hydrazide,
 para-amino-salicylic PAS acid and Protinex from basic raw materials.
 
 - At Chandigarh, the Company has a basic fermentation plant for the
 production of broad spectrum antibiotics, oxytetracycline and
 tetracycline, an organic synthesis unit for chloropropamide, and
 facilities for blending and packaging of feed supplements.
 
 1952
 
 
 - The Company set up a plant at Reay Road, Mumbai and commenced
 processing of antibiotic, anti-TB, vitamin, nutritional and steered
 products and a number of other pharmaceuticals and set up plants for
 isonicotinic acid hydrazide and Protinex - a rich protein
 supplement.
 
 1958
 
 - Pfizer, a leading U.S. and International manufacturer of
 pharmaceuticals, chemical, agricultural and other products took over
 the Company and its name was changed to Pfizer (P) Ltd.
 
 1960
 
 - 15,000 Pref. shares redeemed, 25,100 No. of Equity shares issued.
 
 -The parent Pfizer Inc. and Warner Lambert (the parent company of
 Parke
 Davis) agreed to a -billion merger to create the world's fastest
 growing pharma company.
 
 1963
 
 - Rs 100 shares subdivided into shares of Rs 10 each.
 
 1964
 
 - 1,00,000 No. of Equity shares issued.
 
 1965
 
 - The received support from Pfizer Corporation for the development
 of
 new and improved products.  In November, the Company entered into a
 licence agreement with Pfizer Corporation continuing the
 royalty-free
 licence granted to it for the use of Pfizer processes, technical
 knowhow, etc., relating to the manufacture of existing products in
 the
 pharmaceutical, veterinary and agricultural fields and giving the
 Company the right to obtain from Pfizer Corporation by Mutual
 agreement, technical know-how and other assistance relating to the
 manufacture of new items.
 
 - 12,50,000 shares issued.  Entire capital held by Pfizer
 Corporation,
 Panama and its nominees.
 
 1966
 
 - 6,60,000 shares issued in March at a premium of Rs 15 per shares:
 1,98,000 shares taken up by directors, etc. and employees of the
 Company and 4,62,000 shares offer to the public.
 
 1968
 
 - Rs 2 per share called up on Capital Account by 2nd January.  In
 April, 1,800 share forfeited.  In July, 13,29,100 Bonus shares
 issued
 in prop. 1:2.  180 forfeited shares were thus reissued.
 
 - Pfizer is a leader in the pharmaceutical industry, manufacturing
 and
 marketing a diverse range of products.It has a fully owned
 subsidiary
 -- Duchem Laboratories.
  
 
 1972
 
 - In April, 15,94,568 Bonus Equity shares issued in the prop. 2:5.
 
 1977
 
 - The company became public limited company on 4th March.
 
 - The Company has a Process Development Laboratory in Mumbai
 exclusively used for the study and development of new processes for
 the
 basic manufacture of drugs.  It has a Pharmaceutical Product
 Development Laboratory also located in Mumbai.  A large research and
 development laboratory at Thane was commissioned in 1969.
 
 - 44,64,820 Bonus shares issued in prop. 4:5.
 
 1982
 
 - During October the Company issued 16,74,300 new equity shares of
 Rs.
 10 each at a premium of Rs 8 per share to reduce the foreign
 shareholding in the Company to 60%.
 
 1983
 
 - The Company had received in August/September consent order from
 the
 Controller of Capital Issues, to issue 5,37,500 No. of equity
 shares,
 of Rs 10 each for cash at a premium of Rs 10 per share, as `Rights'
 to
 the existing shareholders and also to the employees of the Company,
 in
 connection with the proposed project for the manufacture of
 oleandomycin, polymycin, bacitracin and zinc bacitracin.  
 
 1985
 
 
 - Duchem Laboratories Ltd. (formerly known as United Advertising
 Ltd.)
 and Euphoric Drugs Ltd., are wholly owned subsidiaries of the
 Company.
 Euphoric Drugs Ltd., became a subsidiary of Duchem Laboratories Ltd.
 
 1988
 
 
 - With a view to voluntarily reducing foreign equity shareholding in
 Pfizer Ltd., from 60% to 40%, Pfizer Corporation, U.S.A.  offered
 for
 sale in August 1988, 23,44,050 No. of equity shares out of their
 total
 holding of 70,32,100 shares of Pfizer Ltd.
 
 - The 23,44,050 shares which were offered for sale were allotted at
 a
 price of Rs 30 per share (face value Rs 10 and premium Rs 20) in the
 following manner: (i) 12,30,000 shares to Euphoric Pharmaceuticals
 Pvt.
 Ltd., Gujarat, (ii) 9,37,610 shares to the existing equity
 shareholders
 of the Company in the ratio of 1:5, (iii) 1,17,200 shares to
 employees
 and directors of Pfizer Ltd., and (iv) 59,240 shares to business
 associates of the Company.
 
 1989
 
 
 - Piroxicam, a major anti-artharitic drug, was launched in India in
 the
 last quarter of the year under the brand name DOLONEX.
 
 1990
 
 - During the year, the animal health products division launched
 Distodin for fluke worms in cattle and the division proposed to
 launch
 Terramycin LA a unique sustained release injectable dosage form in
 the
 near future.
 
 - The Company issued 14% Non-Convertible debentures aggregating Rs
 200
 lakhs on private placement basis to ICICI.
 
 1991
 
 - The Company issued 2,00,000-16.5% redeemable non-convertible
 debentures of Rs 100 each to ICICI on private placement basis. 
 These
 debentures are to be redeemed in three equal instalments commencing
 at
 the end of the 6th year and ending at the end of 8th year from the
 date
 of allotment of debentures at a premium of 5% at the end of the 7th
 year.
 
 1992
 
 - The former subsidiary Dumex Ltd., which was amalgamated with
 effect
 from 1st April, with the Company.  During the year, the
 pharmaceuticals
 division introduced `Dolmex' intramuscular injection.
 
 - The animal health products division launched `Coxistac' a latest
 generation ionophore anti-coccidial, specially recommended for the
 boiler industry.
 
 - With effect from 1st April, Dumex Ltd., a wholly owned subsidiary
 of
 the Company was amalgamated with the Company.
 
 - With the reduction in the equity shares holding by Pfizer
 Corporation, the Company ceased to be a FERA company.
 
 1995
 
 - The pharmaceutical division proposed to introduce Gastro
 Intestinal
 Therapeutic System using advanced laser technology for hypertensive
 patients with problem of diabetes, high cholesterol and several
 other
 concomitant diseases.
 
 1996
 
 - Pfizer has acquired the animal healthcare operations of Smithkline
 Beecham.

 The bulk drug plant at Kalyani was sold to Dabur in 1996.
 
 - The pharmaceutical division discontinued combantrin, diabinese and
 two terramycin dosage form.
 
 1998
 
 - An Artihypertasing Amlogard was launched.  It was proposed to
 launch
 a new long-acting endectocide.
 
 - The letter of intent for the new products COMBANTRIN and BANMINTH
 was converted into an industrial licence.  As regards the letter of
 intent for OLEANDOMYCIN, POLYMYCIN, BACITRACIN and ZINC
 BACITRACIN the Company decided not to go ahead with the manufacture
 of
 oleandomycin as it was not found to be economically viable.
 
 - Pfizer India is an affiliate of Pfizer, US, which is the sixth
 largest pharma company in the world.
 
 - In Jan.'99, Pfizer, transferred to itself Magnamycin, a successful
 injectable antibiotic brand, from Duchem, its subsidiary.
 
 1999
 
 
 - Pfizer India has issued a notice that it will close down its
 manufacturing plant at Ankleshwar with effect from 31st July.
 
 - Pfizer Inc the US pharma giant's decision to set up 100 per cent
 subsidiary has given a jolt to investors in Pfizer India.
 
 - As part of the consolidation exercise, the parent company of
 Pfizer
 has also approached the government to set up a 100-per cent
 subsidiary
 in India to manufacture high-tech formulations.
 
 - The Foreign Investment Promotion Board on Monday approved Pfizer's
 proposal to set up a wholly-owned subsidiary while deferring by four
 weeks Honda-Siel Cars' application to become the indenting agents
 for
 Honda Motor Company of Japan.
 
 - Pfizer Inc's proposal to set up a 100 per cent subsidiary in
 India.
 Pfizer Ltd is 40 per cent held by the American parent company.
 
 - Pfizer received approval from the Foreign Investment Promotion
 Board
 to set up a 100 per cent subsidiary, causing concern among minority
 shareholders that the proposed subsidiary would reap the benefits of
 the prospective changes in the patent law.
 
 2000
 
 - Shantha Biotechnics has tied up with the company for parallel
 marketing of its products.
 
 - In July 2000, the company allotted bonus shares in the ratio of
 1:1,
 thereby increasing the paid-up equity capital to Rs 23.44 cr. 
 
 - Mr. Hocne Sidi Said has been appointed as the Managing Director in
 place of Mr Ian R. Young effective from 1st January 2001.  The
 resignation of Mr Bhaskar Bhattacharya, Alternate Director to MR B.
 Balentini and Wholetime Director of the company has been accepted
 with
 effect from 1st December.
 
 - During 1999-2000, the company two products, Hepashield and Magnex
 have been ranked as number one and number two selling brands amongst
 over 700 brands launched by various companies in last 12 months.
 
 2002
 
 -The operational merger between Pfizer and Parke-Davis has been
 completed and the legal merger is underway.
 
 -Pfizer Ltd has informed BSE that Mr Michael Sweitzer has been
 appointed as a Director in the causal vacancy arising out of the
 resignation of Mr P J Santoriella. Mr K Handa, Executive Director,
 Finance who was the Alternate Director to Mr P J Santoriella, has now
 been appointed as an Alternate Director to Mr Michael Sweitzer.
 
 2003
 
 -Pharmacy has agreed to shed an experimental impotence drug to
 satisfy US antitrust
 reguators scrutinising the company's pending with Pfizer.
 
 -The Bombay high court has granted an ad-interim stay on the merger
 of Pfizer
 and Park-Davis on the basis of an appeal made by minor shareholders.
 
 -Biggest multivitamin brand in the Indian market, Becosules a product
 of Pfizer Ltd.
 is expected to Hit 100-cr mark in terms of annual turnover by March
 2003.
 
 -Pfizer has initiated the global implementation of 'Clinicopia
 Labelling and 
 Clinicopia Supply Chain' a part of infoPro's Clinical Trails
 management suite.
 
 -Pfizer's Chief in India has taken over as the managing Director of
 Pharmacia
 Healthcare which is the first step towards their integration.
 
 -Supreme court declines to vacate stay of Bombay High Court on the
 proposed
 drug maker Parke-Davis with Pfizer.
 
 -Pfizer with GlaxoSmithkline have lowered their prices of their AIDS
 drugs for
 state run AIDS drug assistance programmes in the United states.
 
 -Pfizer has successfully completed the operational integration of
 Pharmacia 
 with itself.
 
 -Pfizer has opted for Bharat S Raut & Co as the auditors of the
 company by
 replacing A F Ferguson and Co.
 
 -The Supreme Court has dismissed the petition filed by the
 shareholders challenging the merger of Pfizer Ltd and Parke-Davis
 India Ltd.
 
 -Supreme Court permits Parke-Davis(I) merger with Pfizer,The company
 will issue equity shares in the ratio of 9:4 
 
 -Appointment of Mr Richard Gane as Director on ther Board of the
 company in place of Mr Charles Sarris.
 
 -The strength of the board of Pfizer is cut to almost half, from 11
 to 6.The directors who have stepped down from the board are all
 representatives of the parent company, Pfizer Inc. They are James S
 Hilboldt, Dr Michael Walter Hodin, Michael Sweitzer, Benjamin
 Valentini, Dr Pierre Etienne, Robert Wakefield Norton and Daniel P
 Cronin. The company has filled the two vacant slots by making
 executive director (finance) Kewal Handa and executive director
 (technical operations) B M Gagrat as full-time directors in place of
 R W Norton and James Hilboldt.
 
 2004
 
 -Pfizer Ltd has informed that it has entered into an Agreement with
 Sanofi Synthelabo (India) Ltd for co-promotion of its product, Daxid.
 The agreement is valid for a period of 3 years.
 
 -Pfizer withdraws Gelusil product
 
 -Pfizer subsidiary ties up with Siro Clinpharm
 
 2006
 
 -Pfizer launches two new products
 
 2007
 
 - Pfizer Ltd has informed that the Board of Directors of the Company
 at its meeting held on June 28, 2007 has appointed Mr. Yugesh Goutam,
 Senior Director - Human Resources (HR) as Additional Director on the
 Board of the Company.
 
 2010
 
 - Pfizer Inc. has entered into collaboration with New York-based
 research services and informatics firm TCG Lifesciences Limited to
 develop a portfolio of preclinical candidate molecules in a series of
 discovery target programs.